Revenue and Profitability - The company's revenue for Q1 2024 was ¥146,276,963.82, representing a 17.75% increase compared to ¥124,226,061.67 in the same period last year[5] - Net profit attributable to shareholders decreased by 32.90% to ¥21,532,537.03 from ¥32,088,662.63 year-on-year[5] - Basic and diluted earnings per share fell by 64.07% to ¥0.1988 from ¥0.5533 in the previous year[5] - Operating profit decreased to CNY 24,428,408.78, down 31.2% from CNY 35,551,888.48 in the same period last year[21] - The company reported a total comprehensive income of CNY 21,523,763.06 for Q1 2024, compared to CNY 32,088,662.63 in Q1 2023[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥1,640,883.14, a decline of 111.59% compared to ¥14,153,258.65 in Q1 2023[11] - Cash inflow from investment activities totaled 3,527,905,218.34, with a net cash flow of 209,416,222.37, contrasting with a negative cash flow of -13,409,829.68 in the prior period[23] - The net increase in cash and cash equivalents was 209,036,937.77, compared to 783,423,545.31 in the previous period, showing a decrease in liquidity[24] - The ending balance of cash and cash equivalents was 568,547,454.88, down from 932,397,769.05, indicating a reduction in available cash[24] Assets and Liabilities - Total assets increased by 2.31% to ¥1,503,869,639.53 from ¥1,469,967,974.01 at the end of the previous year[5] - Total liabilities rose to CNY 152,038,788.17, compared to CNY 138,927,726.47 in the previous year[19] - The company's total equity increased to CNY 1,351,830,851.36, up from CNY 1,331,040,247.54 year-over-year[19] - The company reported a total current asset of ¥830,437,539.40, down from ¥878,788,621.84, a decrease of 5.49%[17] Operational Performance - The company's operating costs rose by 50.02% to ¥85,598,444.16, primarily due to an increase in the quantity of products sold[11] - The company experienced a 45.21% increase in selling expenses, amounting to ¥20,930,375.42, attributed to higher promotional costs[11] - The total cash outflow from operating activities was 89,961,054.86, which increased from 86,085,059.99, indicating higher operational costs[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,298[13] - The largest shareholder, Linuo Investment Holdings, holds 34.39% of shares, totaling 37,240,000 shares, with 23,340,000 shares pledged[13] - The total number of preferred shareholders at the end of the reporting period is not applicable[15] - There are no significant changes in the top 10 shareholders due to margin trading activities[14] Investment Activities - Investment activities generated a net cash flow of ¥209,416,222.37, a substantial increase of 1,661.66% compared to -¥13,409,829.68 in Q1 2023[11] - The company invested 3,231,843,016.67 in cash payments for investments, a significant amount reflecting aggressive investment strategies[23] - The cash received from the recovery of investments was 3,526,111,048.66, indicating strong investment recovery efforts[23] Research and Development - Research and development expenses for Q1 2024 were CNY 8,784,714.80, compared to CNY 8,110,172.85 in Q1 2023, reflecting a growth of 8.3%[20] Other Financial Metrics - The weighted average return on equity decreased to 1.60% from 5.99% year-on-year, reflecting a decline of 4.39%[5] - Deferred income tax assets decreased to CNY 2,673,457.45 from CNY 2,924,149.53 year-over-year[18] - The company has a goodwill of ¥1,820,994.04, which was not present in the previous period[17] - Inventory decreased to ¥99,354,540.88 from ¥108,054,744.66, a decline of 8.06%[17] - Non-current assets include long-term equity investments of ¥183,080,078.52, unchanged from the previous period[17] - Accounts receivable rose to ¥76,303,134.71 from ¥43,398,750.30, marking an increase of 75.73%[17]
科源制药(301281) - 2024 Q1 - 季度财报